Last reviewed · How we verify
GD2-CAR-T cell
At a glance
| Generic name | GD2-CAR-T cell |
|---|---|
| Sponsor | The General Hospital of Western Theater Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Alanine aminotransferase increased
- Pyrexia
- Pain in extremity
- Headache
- Anaemia
- Diplopia
- Abdominal distension
- Vomiting
- Swelling
- Jaundice
- Lower respiratory tract infection
- Urinary tract infection
Key clinical trials
- Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (PHASE1)
- Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer (EARLY_PHASE1)
- GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) (PHASE1)
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (PHASE1)
- Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients (PHASE1)
- Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial (PHASE1)
- GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (PHASE1)
- Combination Immunotherapy Targeting Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |